Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Innovent 信 達 生物 製藥 INNOVENT BIOLOGICS , INC . ( Incorporated in the Cayman Islands with Limited Liability ) ( Stock Code : 1801 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board ( the " Board " ) of directors ( the “ Directors ” ) of Innovent Biologics , Inc. ( the " Company " , and together with its subsidiaries , the “ Group " ) is pleased to announce the unaudited condensed consolidated results of the Group for the six months ended 30 June 2021 ( the " Reporting Period ” ) . These interim results have been reviewed by the Company's audit committee and the Company's auditors , Deloitte Touche Tohmatsu . In this announcement , “ we ” , “ us ” and “ our ” refer to the Company and where the context otherwise requires , the Group . Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments , or have been rounded to one or two decimal places . Any discrepancies in any table , chart or elsewhere between totals and sums of amounts listed therein are due to rounding . FINANCIAL HIGHLIGHTS IFRS Measure : Total revenue was RMB1,941.8 million for the six months ended 30 June 2021 , representing an increase of 97.3 % from RMB984.2 million for the six months ended 30 June 2020. Product revenue increased by 101.4 % to RMB1,854.6 million for the six months ended 30 June 2021 , compared to RMB920.9 million in the same period last year , mainly driven by the broader commercialisation activities which led to the continued strong growth of our leading product TYVYT® ( sintilimab injection ) coupled with revenue contribution from three antibody drugs which were launched in the second half of 2020 and a newly approved drug in June 2021 . Gross profit margin of product sales was 87.3 % for the six months ended 30 June 2021 , increased as compared with 79.9 % for the six months ended 30 June 2020 , primarily due to the significant volume increase and notable manufacturing efficiency improvement as the_6 * 3,000L_stainless steel bioreactor production lines were put in use since the fourth quarter of 2020. The large scale stainless steel bioreactor production lines provided market competitive cost advantage of TYVYTⓇ ( sintilimab injection ) . 1